Call for an instant quote 0345 90 80 161
Open Mon to Fri 09:00 - 17:30 | Sat 09:00 - 16:00 (GMT)
19 December 2017 10:13
Around 7,400 British women are diagnosed with ovarian cancer each year
A breakthrough ovarian cancer treatment has been launched in Britain, with the potential to prolong patients' lives and hold back the cancer - reducing relapse times.
The once-a-day pill, named Niraparib, is part of a new class of drugs that target cancers with defective DNA repair systems.
New hope for patients
This latest trial shows Niraparib can massively increase the length of time before cancer returns following chemotherapy.
Results show that for some women - those with an inherited BRCA gene mutation - the length of time before reoccurrence increased from five and a half months to 21 months, when compared with patients undergoing chemotherapy treatment alone.
The study also shows that women without the BRCA mutation benefit from the drug, experiencing double their relapse times.
"Niraparib is the first treatment of its class licensed to delay the progression of ovarian cancer following platinum-based chemotherapy, regardless of BRCA status," says Professor Jonathan Ledermann, from the University College London Cancer Institute.
He continued: "This represents a critical milestone in the management of ovarian cancer. Access to effective and tolerable medicines is sorely needed and the hope is that niraparib will be available in the NHS as quickly as possible."
'Nationwide roll-out'
Around 7,400 women are diagnosed with ovarian cancer each year in Britain, with around 85% of patients seeing it reoccur after treatment.
The cost of the treatment and benefits to the patients are weighed up by the National Institute for Health and Care Excellence (Nice) in England and Wales and the Scottish Medicines Consortium in Scotland.
Katherine Taylor, chief executive of the charity Ovarian Cancer Action, said: "Today's news is an encouraging step in the right direction but we now need to ensure all UK women diagnosed with recurrent platinum-sensitive ovarian cancer can benefit.
"We call upon the National Institute for Health and Care Excellence and the Scottish Medicines Consortium to approve this drug to provide more treatment options for those diagnosed with ovarian cancer - for many women this could be life changing."
Whatever stage your cancer is at, we may still be able to cover you for holidays and overseas travel with our specialist cancer travel insurance.
15 November 2018
Smokers who regularly use vapers are more likely to try and quit smoking for good, new research has suggested.
[more...]
14 November 2018
Leukaemia patients are now a step closer to personalised treatments after a British study looked at the role gene mutations play in blood cancers.
13 November 2018
A quick scan of the blood vessels in a patient's neck could soon be a critical part of future dementia screening, new research has suggested.
10 November 2018
The NHS spends more than £1 billion a year on prescriptions for people with diabetes, new figures show.
09 November 2018
Woman who smoke, have diabetes, or high blood pressure are more likely to suffer a heart attack than men with the same risk factors, a new study claims.
08 November 2018
Millions of UK pensioners feel they don't have anyone they can turn to for help, a leading charity has warned.
07 November 2018
Over a quarter of medical workers are still reluctant to recommend e-cigarettes to smokers despite being told to do so by health authorities, a new survey has revealed.
06 November 2018
A new direct flight between Manchester and Mumbai could boost the economy of northern England to the tune of £400 million, a new report suggests.
02 November 2018
Air travellers could soon face restrictions on the amount of alcohol they can drink before flying, under plans currently being considered by the government.
01 November 2018
A vegan diet could help people living with diabetes to better manage their condition, a new review suggests.
31 October 2018
Electric planes could soon be flying on short-haul routes in Europe, according to the boss of EasyJet.
30 October 2018
UK air travellers waste up to £175 million every year on seat allocations that they don't need, a new study has revealed.